Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 6/20 | 0.43 |
| ▸ | TTK | P33981 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641355 | 0.88 | BTK (0.48) | ITKTTKEGFRJAK3BTK | |
| SCHEMBL29641406 | 0.86 | TTK (0.42) | ITKTTKEGFRCDK4CCND1 | |
| SCHEMBL29729815 | 0.85 | CDK4 (0.50) | EGFRCDK4CCND1PTK2JAK3 | |
| SCHEMBL29641411 | 0.82 | TTK (0.59) | TTKEGFRPTK2JAK3BTK | |
| SCHEMBL29641388 | 0.82 | TTK (0.59) | TTKEGFRPTK2JAK3BTK | |
| SCHEMBL29641325 | 0.81 | PTK2 (0.40) | ITKTTKCDK4CCND1PTK2 | |
| SCHEMBL29729618 | 0.81 | FGFR1 (0.48) | EGFRCDK4CCND1PTK2JAK3 | |
| SCHEMBL29729670 | 0.81 | FGFR1 (0.45) | EGFRCDK4CCND1PTK2JAK3 | |
| SCHEMBL29641322 | 0.80 | WEE1 (0.40) | PTK2JAK3BTKJAK2 | |
| SCHEMBL22689949 | 0.78 | IRAK4 (0.52) | EGFRPTK2JAK3BTKERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220242870-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | VORONOIBIO INC. (KR) | 2022-08-04 | — | — | US | claimed |
| EP-3971190-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Voronoi Inc. (KR) | 2022-03-23 | — | — | EP | claimed |
| US-20220242870-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | VORONOIBIO INC. (KR) | 2022-08-04 | — | — | US | disclosed |
| EP-3971190-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Voronoi Inc. (KR) | 2022-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242870-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | CDK4, CDK6, CDK16 | ITK 260/4885TTK 34/4885EGFR 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.